Answers are grounded in this paper and cite their sources.
Background Bosutinib, a selective Src/c-Abl inhibitor approved for the treatment of chronic myelogenous leukemia (CML), was identified as a molecularly targeted therapeutic candidate for amyotrophic lateral sclerosis (ALS) through induced pluripotent stem cell-based drug repurposing. To evaluate its safety and tolerability and explore its efficacy in ALS, an exploratory, multicenter, open-label phase 2 clinical trial was conducted. Methods This study included a 12-week observation period and a 24-week treatment period enrolling patients diagnosed with ALS within 2 years of symptom onset. Eligible patients were centrally allocated (1:1) to receive oral bosutinib at either 200 mg/day or 300 mg/day for 24 weeks. In lieu of a placebo control arm, efficacy was assessed using two external control datasets: placebo data of the edaravone Study MCI186-19 and registry data from the multicenter ALS cohort study, JaCALS, with outcomes evaluated by the total ALS Functional Rating Scale-Revised (ALSFRS-R). Results Between April 2022 and January 2024, 33 participants were screened, and 26 received bosutinib. Of these, 22 completed the 24-week treatment period and 4 discontinued treatment, primarily because of adverse events, with hepatic toxicity being the most common reason for discontinuation. No new safety signals specific to patients with ALS were identified. As a primary endpoint, the mean change from baseline in ALSFRS-R score at week 24 showed a smaller reduction in both dose groups compared with the placebo group in MCI186-19. The exploratory JaCALS comparison suggested a potential clinical signal of bosutinib. Exploratory biomarker analyses showed a decrease in plasma neurofilament light chain levels after treatment. Conclusions This early-phase study provides safety and tolerability data and exploratory efficacy findings for bosutinib in ALS. It also illustrates both the potential utility and limitations of external controls in a rare, rapidly progressive disease. Trial registration This trial was registered with ClinicalTrials.gov (NCT04744532) on February 9, 2021.
No takes yet. Share an insight, caveat, or question.
Imamura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: